Advanced Cell Technology Inc. - ACTC

Advanced Cell Technology Inc. (ACTC)
http://www.advancedcell.com/
Coverage: March 27, 2006 - September 27, 2006
Featured: March 27, 2006

Latest Newsletter Editions

spacer
Thu, Sep 21, 2006 @ 05:09 pm
Comments in the BLOG There was a new BLOG posting this week on HDY. For those who remember that special situation, the news looks reasonably promising. Monday's BLOG forecasting the break out of CPNE proved prophetic, and the stock is now holding onto the $1.40 level- a new multi month high. I believe...
Wed, Sep 6, 2006 @ 02:09 pm
Wake Me Up When September Ends as my memory rests but never forgets what I lost wake me up when september ends Greenday from the song Wake Me Up When September Ends The lyrics from Greenday's hit song are worth remembering this time of year. Why? - did you know September is historically the worst month...
Sun, Sep 3, 2006 @ 10:09 am
Advanced Cellular (OTC BB: ACTC): High Profile News Fuels Wild Roller Coaster Ride The last two weeks of August are generally the quietest of the year. Not so for ACTC, the subject of my last two editions. Today will make three in a row- unprecedented in the 8 year history of the OTC Journal. Prior...
Sat, Aug 26, 2006 @ 11:08 am
Advanced Cellular (OTC BB: ACTC) Capital Raise Resets the Bar There isn't much else to write about this weekend. ACTC was clearly the story of the week in an otherwise dull, listless, last week of summer. However, ACTC is providing all the fireworks we need for a little excitement. Earlier this past...
Thu, Aug 24, 2006 @ 06:08 am
ACTC: Biggest Percentage One Day Gain Ever in OTC Journal That move happened in conjunction with the publication of the NY Times article which you can read (by referring back to the link above). In light of the kinds of research going on at ACTC, this is the kind of event that could easily happen in...

Click Here For More Newsletters on ACTC

spacer

Latest Blog Entries

spacer

Quote Data

spacer
Last Trade: 0.0799 Bid: 0.0000
Last Size: 0 Ask: 0.0000
Trade Time: 3:55pm Bid x Ask Size: N/A
Change: +0.0000 (+0.00%) Day's Range: 0.00 - 0.00
Prev Close: 0.0799 52wk Range: 0.00 - 0.00
Open: 0.0000 P/E (ttm): N/A
Volume: 0 EPS (ttm): -0.0480
spacer [Chart]

Business Summary

spacer
Advanced Cell Technology, Inc., a biotechnology company, engages in the development and commercialization of human stem cell technology in the fields of regenerative medicine and stem cell therapy in the United States. The company offers RPE cells for the treatment of age-related disease of the eye, including macular degeneration; hemangioblast cells for the treatment of various blood and cardiac disorders; and dermal cells for the treatment of dermal damage, including burns, wound repair, and surgery. It also develops and commercializes products for use in treatment of an array of chronic degenerative diseases and in regenerative repair of acute disease, such as trauma, infarction, and burns. The company, formerly known as A.C.T. Holdings, Inc., was founded in 1994 and is headquartered in Alameda, California.

Disclosure

spacer
MarketByte LLC has been paid a fee of $30,000 and 250,000 warrants, exercisable at $2.54, by Advanced Cell Technology for coverage of the company.

Recent News Headlines

spacer
Ocata Therapeutics Receives Three New U.S. Patents for its RPE Therapy for Macular Degenerative Diseases
Tue, 26 May 2015 13:19:12 GMT
[at noodls] - Patent Portfolio Expanded to Cover RPE Products from All Pluripotent Stem Cell Sources MARLBOROUGH, Mass.-- Ocata Therapeutics, Inc. ('Ocata' or 'the Company'; NASDAQ: OCAT), a leader in the field of Regenerative ...
8:55 am Ocata Therapeutics announces approval for three new US patents, which expand the scope of its existing patents, regarding its retinal pigment epithelium transplant technology
Tue, 26 May 2015 12:55:00 GMT
Ocata Therapeutics Receives Three New U.S. Patents for its RPE Therapy for Macular Degenerative Diseases
Tue, 26 May 2015 12:54:00 GMT
[Business Wire] - Ocata Therapeutics, Inc. , a leader in the field of Regenerative Ophthalmology™, today announced that the United States Patent and Trademark Office issued three new U.S.
Ocata Therapeutics to Present at the Jefferies 2015 Global Healthcare Conference
Mon, 18 May 2015 12:37:15 GMT
[at noodls] - Additional Presentations at the London Regenerative Medicine Network and 10th Annual World Stem Cells & Regenerative Medicine Congress 2015 MARLBOROUGH, Mass.-- Ocata Therapeutics, Inc. ('Ocata'; NASDAQ: ...
Ocata Therapeutics to Present at the Jefferies 2015 Global Healthcare Conference
Mon, 18 May 2015 12:00:00 GMT
Ocata Therapeutics to Present at the Jefferies 2015 Global Healthcare Conference
Mon, 18 May 2015 12:00:00 GMT
[Business Wire] - Ocata Therapeutics, Inc. , a leader in the field of regenerative ophthalmology, today announced that Paul Wotton, Ph.D., President and Chief Executive Officer, will present a company overview at the Jefferies 2015 Global Healthcare Conference on Monday, June 1, 2015 at 2:00 p.m.
OCATA THERAPEUTICS, INC. Financials
Fri, 15 May 2015 17:04:35 GMT
Dr Robert Lanza, Chief Scientific Officer of Ocata Therapeutics to be a Featured Speaker at The Common Good Forum
Mon, 11 May 2015 14:37:52 GMT
[at noodls] - MARLBOROUGH, Mass.-- Ocata Therapeutics, Inc. ('Ocata' or 'the Company'; NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that Robert Lanza, M.D., will be a featured ...
Dr Robert Lanza, Chief Scientific Officer of Ocata Therapeutics to be a Featured Speaker at The Common Good Forum
Mon, 11 May 2015 13:00:00 GMT
[Business Wire] - Ocata Therapeutics, Inc. , a leader in the field of Regenerative Ophthalmology™, today announced that Robert Lanza, M.D., will be a featured speaker at The Common Good Forum “Venture Economics, Public Policy & Investment: Our Nation’s Future” on May 14, 2015, at the Waldorf Astoria in New York City.
10-Q for Advanced Cell Technology, Inc.
Sun, 10 May 2015 00:09:44 GMT
OCATA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
Thu, 07 May 2015 20:27:13 GMT
10-K for Advanced Cell Technology, Inc.
Tue, 05 May 2015 00:12:39 GMT
Ocata Therapeutics to Host Conference Call and Webcast to Provide Corporate Update for the First Quarter of 2015
Mon, 04 May 2015 13:33:14 GMT
[at noodls] - Call Scheduled for Thursday, May 7, 2015 at 4:30 P.M. MARLBOROUGH, Mass.-- Ocata Therapeutics, Inc. ('Ocata' or 'the Company'; NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, announced ...
Ocata Therapeutics to Host Conference Call and Webcast to Provide Corporate Update for the First Quarter of 2015
Mon, 04 May 2015 12:00:00 GMT
[Business Wire] - Ocata Therapeutics, Inc. , a leader in the field of Regenerative Ophthalmology™, announced today that it will host a conference call on Thursday, May 7, 2015 at 4:30 p.m.
Ocata Therapeutics Announces Positive Results in Treating Macular Degeneration Using Fully Differentiated Stem Cell-Derived Retinal Pigment Epithelium (RPE) Cells in Asian Patients
Thu, 30 Apr 2015 16:37:36 GMT
[at noodls] - Study Sponsored by CHA Biotech in South Korea Supports Earlier Findings Reported in The Lancet MARLBOROUGH, Mass.-- Ocata Therapeutics, Inc. ('Ocata' or 'the Company'; NASDAQ: OCAT), a leader in the field ...
Ocata Therapeutics Announces Positive Results in Treating Macular Degeneration Using Fully Differentiated Stem Cell-Derived Retinal Pigment Epithelium (RPE) Cells in Asian Patients
Thu, 30 Apr 2015 16:30:00 GMT
[Business Wire] - NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, announced that a study has been published that includes top-line, positive results in Asian patients who were treated with Ocata’s proprietary RPE cells, manufactured using its DeltaCell™ Technology. “The results of this study conducted by CHA Biotech in Asian patients support the findings published in The Lancet in October 2014 and further underscores our leadership in regenerative ophthalmology,” said Paul K. Wotton, Ph.D., President and Chief Executive Officer.
Ocata Therapeutics Announces Positive Results in Treating Macular Degeneration Using Fully Differentiated Stem Cell-Derived Retinal Pigment Epithelium (RPE) Cells in Asian Patients
Thu, 30 Apr 2015 16:30:00 GMT
[Business Wire] - Ocata Therapeutics, Inc. , a leader in the field of Regenerative Ophthalmology™, announced that a study has been published that includes top-line, positive results in Asian patients who were treated with Ocata’s proprietary RPE cells, manufactured using its DeltaCell™ Technology.
Dr Robert Lanza, Chief Scientific Officer of Ocata Therapeutics to Deliver Opening Address at the Massachusetts State Science & Engineering Fair
Tue, 28 Apr 2015 13:02:00 GMT
[Business Wire] - Ocata Therapeutics, Inc. , a leader in the field of Regenerative Ophthalmology™, today announced that its chief scientific officer, Robert Lanza, M.D., will be delivering the opening address to the judges and students at the Massachusetts State Science & Engineering Fair being held at the Massachusetts Institute of Technology, in Cambridge, MA on May 1st, 2015.
Ocata Therapeutics Successfully Completes Dosing in Phase 1/2 RPE Studies
Tue, 31 Mar 2015 13:05:35 GMT
[at noodls] - SMD Pivotal Trial and AMD Phase 2 Trial to be Initiated MARLBOROUGH, Mass.-- Ocata Therapeutics, Inc. ("Ocata"; NASDAQ:OCAT), a leader in the field of regenerative ophthalmology, today announced ...
Ocata Therapeutics Successfully Completes Dosing in Phase 1/2 RPE Studies
Tue, 31 Mar 2015 12:58:00 GMT
[Business Wire] - Ocata Therapeutics, Inc. , a leader in the field of regenerative ophthalmology, today announced that the company has completed dosing of its Phase 1/2 studies for dry age-related macular degeneration and Stargardt’s Macular Degeneration .